Literature DB >> 23974722

Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection.

Andrew D Cox1, Frank St Michael, Annie Aubry, Chantelle M Cairns, Philippa C R Strong, Alexander C Hayes, Susan M Logan.   

Abstract

A lipoteichoic acid has recently been shown to be conserved in the majority of strains from Clostridium difficile and as such is being considered as a possible vaccine antigen. In this study we examine the candidacy of the conserved lipoteichoic acid by demonstrating that it is possible to elicit antibodies against C. difficile strains following immunisation of rabbits and mice with glycoconjugates elaborating the conserved lipoteichoic acid antigen. The present study describes a conjugation strategy that utilises an amino functionality, present at approximately 33 % substitution of the N-acetyl-glucosamine residues within the LTA polymer repeating unit, as the attachment point for conjugation. A maleimide-thiol linker strategy with the maleimide linker on the carboxyl residues of the carrier protein and the thiol linker on the carbohydrate was employed. Immunisation derived antisera from rabbits and mice, recognised all strains of C. difficile vegetative cells examined, despite an immune response to the linkers also being observed. These sera recognised live cells in an immunofluorescence assay and were also able to recognise the spore form of the bacterium. This study has illustrated that the LTA polymer is a highly conserved surface polymer of C. difficile that is easily accessible to the immune system and as such merits consideration as a vaccine antigen to combat C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23974722     DOI: 10.1007/s10719-013-9489-3

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  26 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic.

Authors:  Matthias A Oberli; Marie-Lyn Hecht; Pascal Bindschädler; Alexander Adibekian; Thomas Adam; Peter H Seeberger
Journal:  Chem Biol       Date:  2011-05-27

Review 3.  The host immune response to Clostridium difficile.

Authors:  Ciarán P Kelly; Lorraine Kyne
Journal:  J Med Microbiol       Date:  2011-03-17       Impact factor: 2.472

4.  Immunological evaluation of a synthetic Clostridium difficile oligosaccharide conjugate vaccine candidate and identification of a minimal epitope.

Authors:  Christopher E Martin; Felix Broecker; Matthias A Oberli; Julia Komor; Jochen Mattner; Chakkumkal Anish; Peter H Seeberger
Journal:  J Am Chem Soc       Date:  2013-06-24       Impact factor: 15.419

5.  Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera.

Authors:  Andrew D Cox; Frank St Michael; Chantelle M Cairns; Suzanne Lacelle; Amy Lea Filion; Dhamodharan Neelamegan; Cory Q Wenzel; Heather Horan; James C Richards
Journal:  Glycoconj J       Date:  2011-05-18       Impact factor: 2.916

6.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

7.  Immunochemistry of the cell-surface carbohydrate antigens of Clostridium difficile.

Authors:  I R Poxton; T D Cartmill
Journal:  J Gen Microbiol       Date:  1982-06

8.  Immunological analysis of the EDTA-soluble antigens of Clostridium difficile and related species.

Authors:  I R Poxton; M D Byrne
Journal:  J Gen Microbiol       Date:  1981-01

9.  Measures to control and prevent Clostridium difficile infection.

Authors:  Dale N Gerding; Carlene A Muto; Robert C Owens
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

10.  Structural characterization of surface glycans from Clostridium difficile.

Authors:  Christopher W Reid; Evgeny Vinogradov; Jianjun Li; Harold C Jarrell; Susan M Logan; Jean-Robert Brisson
Journal:  Carbohydr Res       Date:  2012-02-23       Impact factor: 2.104

View more
  17 in total

Review 1.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 2.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

3.  An atypical lipoteichoic acid from Clostridium perfringens elicits a broadly cross-reactive and protective immune response.

Authors:  Cory Q Wenzel; Dominic C Mills; Justyna M Dobruchowska; Jiri Vlach; Harald Nothaft; Patrick Nation; Parastoo Azadi; Stephen B Melville; Russell W Carlson; Mario F Feldman; Christine M Szymanski
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

4.  Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct.

Authors:  Kevin A Henry; Henk van Faassen; Doreen Harcus; Anne Marcil; Jennifer J Hill; Serge Muyldermans; C Roger MacKenzie
Journal:  Immunogenetics       Date:  2019-01-18       Impact factor: 2.846

5.  Immunogenicity and protective efficacy of Clostridium difficile spore proteins.

Authors:  Chandrabali Ghose; Ioannis Eugenis; Adrianne N Edwards; Xingmin Sun; Shonna M McBride; David D Ho
Journal:  Anaerobe       Date:  2015-12-11       Impact factor: 3.331

Review 6.  Novel approaches to treating Clostridium difficile-associated colitis.

Authors:  David Padua; Charalabos Pothoulakis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-07       Impact factor: 3.869

7.  Synthetic teichoic acid conjugate vaccine against nosocomial Gram-positive bacteria.

Authors:  Diana Laverde; Dominique Wobser; Felipe Romero-Saavedra; Wouter Hogendorf; Gijsbert van der Marel; Martin Berthold; Andrea Kropec; Jeroen Codee; Johannes Huebner
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

Review 8.  An update on antibody-based immunotherapies for Clostridium difficile infection.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Clin Exp Gastroenterol       Date:  2016-08-01

9.  A Clostridium difficile Cell Wall Glycopolymer Locus Influences Bacterial Shape, Polysaccharide Production and Virulence.

Authors:  Michele Chu; Michael J G Mallozzi; Bryan P Roxas; Lisa Bertolo; Mario A Monteiro; Al Agellon; V K Viswanathan; Gayatri Vedantam
Journal:  PLoS Pathog       Date:  2016-10-14       Impact factor: 6.823

10.  Clostridium difficile surface proteins are anchored to the cell wall using CWB2 motifs that recognise the anionic polymer PSII.

Authors:  Stephanie E Willing; Thomas Candela; Helen Alexandra Shaw; Zoe Seager; Stéphane Mesnage; Robert P Fagan; Neil F Fairweather
Journal:  Mol Microbiol       Date:  2015-03-06       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.